CD8A and cancer: In conclusion, the TME spatial biomarkers for pathological response to ICI combination treatment in UC validated in an HNSCC cohort, suggesting that the SRs between CD8+ T cells and macrophages to cancer cells could be an important context-independent biomarker for clinical response to ipilimumab+nivolumab.